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Mast cells have been shown to express vascular endothelial growth factor (VEGF),
thereby implicating mast cells in pro-angiogenic processes. However, the mechanism
of VEGF induction in mast cells and the possible expression of VEGF in fully mature
mast cells have not been extensively studied. Here, we report that terminally differen-
tiated peritoneal cell-derived mast cells can be induced to express VEGF in response
to challenge with Staphylococcus aureus, thus identifying a mast cell–bacteria axis as
a novel mechanism leading to VEGF release. Whereas live bacteria produced a robust
upregulation of VEGF in mast cells, heat-inactivated bacteria failed to do so, and bacte-
ria-conditioned media did not induce VEGF expression. The induction of VEGF was not
critically dependent on direct cell–cell contact between bacteria and mast cells. Hence,
these findings suggest that VEGF can be induced by soluble factors released during the
co-culture conditions. Neither of a panel of bacterial cell-wall products known to activate
toll-like receptor (TLR) signaling promoted VEGF expression in mast cells. In agreement
with the latter, VEGF induction occurred independently of Myd88, an adaptor molecule
that mediates the downstream events following TLR engagement. The VEGF induction
was insensitive to nuclear factor of activated T-cells inhibition but was partly dependent
on the nuclear factor kappa light-chain enhancer of activated B cells signaling pathway.
Together, these findings identify bacterial challenge as a novel mechanism by which
VEGF is induced in mast cells.
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inTrODUcTiOn
Mast cells are tissue-resident cells located at the host–environment interface. They express numer-
ous immune receptors and host a multitude of immunological mediators (1–3). While generally 
known for their involvement in allergy (4), mast cells have also implicated in numerous additional 
pathological settings, ranging from defense against bacterial infections (5) to an involvement in 
malignant processes (6). In the latter context, mast cells have, in particular, been implicated to sup-
port angiogenesis, thereby promoting tumor growth and metastasis (7, 8).
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In the angiogenic process, vascular endothelial growth factor 
(VEGF) has a key role by promoting endothelial cell survival, 
proliferation, and migration (9). Moreover, VEGF has been found 
to exert a chemoattractant effect on immune cells (10). In sup-
port for the notion that mast cells are involved in angiogenesis, 
human, rat, and murine mast cells have been shown to synthesize 
and secrete VEGF. Previous work has shown that mast cells can 
release VEGF in response to IgE receptor cross-linking, through 
stimulation of c-kit, by challenge with a protein kinase C activa-
tor (phorbol myristate acetate) or calcium ionophore (11,  12). 
Additionally, mast cells have been shown to release VEGF in 
response to PGE2 activation through the EP(2) receptor (13), 
and the adenosine analog [5′-N-ethylcarboxamido adenosine 
(NECA)] has been reported to increase VEGF expression in 
human lung mast cells (14).
In a previous study, we studied the impact of Staphylococcus 
aureus (S. aureus) on gene expression patterns in mast cells (15). 
As judged by gene array data, we found that live S. aureus induced 
the expression of numerous pro-inflammatory genes such as 
various cytokines and chemokines. Somewhat unexpectedly, we 
also found that VEGF was markedly upregulated. In fact, the gene 
array experiment indicated that the VEGF gene was induced to 
a higher extent than most other genes. Since no previous study 
has suggested a link between bacterial infection and induction of 
VEGF in mast cells, we, here, investigated the relevance of this 
finding. Moreover, since most of the previous studies in which 
mast cells have been shown to express VEGF were performed 
using relatively immature mast cells, we also sought to investigate 
whether fully mature mast cells can be induced to express VEGF. 
Indeed, we here provide evidence that live S. aureus induces 
high levels of VEGF expression in terminally differentiated mast 
cells. Hence, our findings provide a hitherto unrecognized link 
between mast cells and VEGF expression in the context of bacte-
rial infection.
MaTerials anD MeThODs
Bacteria and conditioned Media
Staphylococcus aureus (strain 8325-4) was streaked on horse blood 
agar plates (5%; National Veterinary Institute, Uppsala, Sweden) 
and incubated at 37°C for 24 h. Liquid cultures were started by 
inoculating 20 ml of Tryptone Soy Broth (TSB; BD) followed by 
incubation at 37°C and 150 rpm for 16 h. Two hundred microlit-
ers of this overnight culture were used to inoculate 20 ml of fresh 
TSB followed by incubation at 37°C and 150 rpm to an OD600 of 
1.0. Conditioned media were produced by culturing S. aureus in 
20 ml of TSB or antibiotic-free peritoneal cell-derived mast cells 
(PCMCs) media for 24 h at 37°C. The bacteria were removed by 
centrifugation (6000 × g for 5 min) followed by sterile filtration 
through 0.2 μm filters. Sterility was checked by plating a 100-μl 
aliquot onto horse blood agar followed by incubation at 37°C for 
24 h.
Peritoneal cell-Derived Mast cells
Peritoneal cell-derived mast cells (PCMCs) were established 
according to a published protocol (16). Briefly, peritoneal lavage 
of mice was performed, followed by culture of the peritoneal cells 
in DMEM plus GlutaMAX (Gibco, Invitrogen, Paisley, UK) sup-
plemented with 10% supernatant of stem cell factor-transfected 
Chinese hamster ovary cells (a gift from Dr. M. Daeron, Pasteur 
Institute, France), 10% fetal bovine serum, 50  μg/ml strepto-
mycin, 60 μg/ml penicillin, 10 mM MEM non-essential amino 
acids, and 50 μM 2-mercaptoethanol. The medium was changed 
every 3–4 days. The inclusion of stem cell factor in the medium 
promotes the expansion of mast cells at the expense of other peri-
toneal cell populations. After ~1 month, pure mast cell cultures 
were obtained, as judged by toluidine blue staining.
Mice
Female mice of the C57BL/6 background were used for the 
experiments. All animal experiments were approved by the local 
ethical committee (Uppsala djurförsöksetiska nämnd; C31/14).
In Vitro exposure of PcMcs to S. aureus, 
Bacterial cell-Wall components, and 
conditioned Media
PCMCs were washed twice in PBS and re-suspended in 
antibiotic-free PCMC medium and plated in 24-well tissue 
plates at a density of 0.5 × 106 cells per replicate. Alternatively, 
PCMCs were plated in Transwell plates (0.4 μm pores; Costar). 
For inhibition experiments, PCMCs were pretreated with 10 μM 
nuclear factor of activated T-cells (NFAT) inhibitor (11R-VIVIT; 
Calbiochem, Darmstadt, Germany), 200  nM nuclear factor 
kappa light-chain enhancer of activated B cells (NF-κβ) inhibi-
tor [6-amino-4-(4-phenoxyphenylethylamino)quinazoline] for 
1 h, or with 45 μM Myd88 inhibitor (Pepinh-MYD and control 
peptide Pepinh-Control) for 6 h prior to infection. The bacteria 
were washed twice in PBS and added to the PCMC cultures at a 
final concentration of ~1.25 × 107 CFU/ml; multiplicity of infec-
tion (MOI) 25. For inactivation experiments, the bacteria were 
heat inactivated (HIA) at 60°C for 1 h. Conditioned media were 
added at a volume corresponding to that of the added bacteria. 
Purified bacterial cell-wall components: lipopolysaccharide 
(LPS; 1 μg/ml), lipoteichoic acid (LTA; 1 μg/ml), peptidoglycan 
(PGN; 10 μg/ml), or Pam3CSK4 (PAM3; 0.5 μg/ml) were added 
in some experiments. At various time points after infection, 
cells were collected by centrifugation (6000 × g; 5 min). Media 
and cell fractions were frozen and stored at −20 and −80°C, 
respectively. All experiments were performed in quadruplicates.
rna Preparation and Quantitative real-
Time Pcr
Quantitative real-time PCR (qPCR) was performed as described 
(17). Briefly, total RNA from the co-culture pellets was isolated 
using the NucleoSpin RNA II kit (Macherey-Nagel, Düren, 
Germany). qPCR was performed using the SYBR GreenER 
qPCR Supermix Universal Mastermix (Invitrogen, Waltham, 
MA, USA) on an ABI 7900HT Fast Real-Time PCR System 
(Applied Biosystems). The following primers were used: 
VEGF forward, 5′-GGAGTCTGTGCTCTGGGATT and VEGF 
reverse, 5′-AACCAACCTCCTCAAACCGT. HPRT forward, 
5′-GATTAGCGATGATGAACCAGGTTA and HPRT reverse, 
FigUre 1 | co-culture of PcMcs and S. aureus induces the 
expression and release of vascular endothelial growth factor (VegF). 
Mast cells (PCMCs) were co-cultured with S. aureus (SA) with PBS as 
negative control. Cell fractions were taken at indicated time points, and 
VEGF expression was measured by qPCR (a). Release of VEGF protein was 
measured by ELISA (B). Results are given as mean ± SD, ****p < 0.0001 
(n = 4).
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5′-GACATCTCGAGCAAGTCTTTCAGTC. Melt curve analy-
ses of all qPCR products were performed. Relative expression 
of the VEGF gene in comparison with the house keeping gene 
(HPRT) was calculated, as previously described (17).
elisas
ELISAs for murine VEGF (PeproTech) were performed accord-
ing to the manufacturer’s instructions.
statistical analysis
Statistical analyses were performed using one-way ANOVA with-
out matching and Fisher’s LSD post hoc test. The analyses were 
carried out with GraphPad Prism 6 (GraphPad Software). The 
results shown are from individual experiments, representative for 
at least two experiments.
resUlTs
S. aureus induces VegF expression and 
release in cultured Peritoneal cell-
Derived Mast cells
To investigate whether S. aureus can affect VEGF expression 
in mast cells, terminally differentiated peritoneal cell-derived 
mast cells (PCMCs; 0.5  ×  106) were co-cultured with live 
S. aureus (MOI = 25). Cell pellets and supernatants were col-
lected after 2, 6, and 24  h. Total RNA from cell pellets was 
used for reverse transcription and qPCR. Supernatants were 
analyzed by ELISA for content of VEGF protein. As shown in 
Figure  1A, VEGF gene expression was highly induced in the 
PCMCs after co-culture with the live S. aureus. Notably, VEGF 
expression was modest after 2  h of co-culture and reached a 
maximum after 6 h.
Increased VEGF gene expression was also accompanied by 
release of VEGF protein as determined by ELISA. As depicted 
in Figure 1B, VEGF release was seen from 2 h and onward, with 
gradually increasing accumulation of VEGF in the medium up 
to 24 h.
live S. aureus induces VegF expression 
in Mast cells independent of Bacterial 
cell-Wall components
To approach the mechanism by with the bacteria induce VEGF 
expression in mast cells, we investigated the possibility that 
VEGF is induced by various toll-like receptor (TLR) ligands that 
are expressed by bacteria. To this end, PCMCs were stimulated 
with typical cell-wall components of Gram-positive bacteria: 
lipoteichoic acid (LTA), PGN, or Pam3CSK4 (PAM3). In addi-
tion, we assessed the effect of LPS, i.e., the prototype cell-wall 
component of Gram-negative bacteria. The bacterial products 
were added to the mast cells, either alone or in combination, 
followed by measurement of VEGF gene expression. However, 
neither of these TLR ligands induced VEGF expression in 
PCMCs (Figure  2A), suggesting that bacteria induce VEGF 
by mechanisms in mature mast cells independent of bacterial 
cell-wall compounds and TLR signaling. In agreement with this 
notion, inhibition of Myd88, an adaptor molecule common for 
most TLR signaling pathways, did not reduce the expression of 
VEGF in response to stimulation of mast cells by live S. aureus 
(Figure 2B).
Next, we assessed whether VEGF induction requires that the 
bacteria are alive, by investigating the effect of heat-inactivated 
bacteria on VEGF expression in mast cells. As seen in Figure 2C, 
HIA S. aureus did not induce VEGF expression above baseline 
levels, indicating that it is essential that the bacteria are alive to be 
able to induce VEGF expression in mature mast cells. Moreover, 
since most bacterial cell-wall components are not affected by heat 
inactivation, this finding further supports that the VEGF induc-
tion in mast cells is not mediated by cell-wall components of S. 
aureus.
As VEGF expression was not induced by any of the tested 
cell-wall compounds, we assessed the possibility that S. aureus 
secrete soluble compounds that might drive VEGF expression. 
To test this, we collected conditioned media from S. aureus, hav-
ing non-conditioned medium as control. For this experiment, 
S. aureus was either cultured in bacterial growth medium (TSB) 
or in the medium used for culture of the PCMCs. However, 
FigUre 2 | The induction of VegF expression in PcMcs requires live 
bacteria.  
(Continued)
(a) VEGF mRNA expression in PCMCs in response to bacterial cell-wall 
components alone or in combination (“Cocktail”): lipopolysaccharide (LPS; 
1 μg/ml), lipoteichoic acid (LTA; 1 μg/ml), peptidoglycan (PGN; 10 μg/ml), 
Pam3CSK4 (PAM3; 0.5 μg/ml); PBS, negative control. (B) VEGF mRNA 
expression in PCMCs preincubated with Myd88 inhibitor (Pepinh-MYD) or 
with Pepinh-Control (control for the Myd88 inhibitor; Myd88C) followed by 
co-culture with S. aureus (SA) for 2 or 6 h. (c) VEGF expression in response 
to heat-inactivated (HIA) S. aureus (SA); PBS, negative control. (D,e) VEGF 
expression in PCMCs at 6 h (D) and 24 h (e) in response to S. aureus-
conditioned media. Conditioned media were taken from S. aureus cultured in 
either TSB (bacterial growth medium; C. TSB) or in PCMC medium (C. Cell 
Media), using TSB or PBS as negative controls. Results are given as 
mean ± SD, **p < 0.01, and ****p < 0.0001 (n = 3–4).
FigUre 2 | continued
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neither of these variants of conditioned media induced the 
expression of VEGF in PCMCs (Figures 2D,E).
Optimal induction of VegF expression in 
Mast cell is Dependent of Direct contact 
between Mast cells and Bacteria
To determine whether the induction of VEGF expression in mast 
cells by S. aureus is dependent on physical contact between the 
bacteria and mast cells, PCMCs were co-cultured with S. aureus 
in a Transwell system in which the mast cells and bacteria were 
separated by a 0.4-μm membrane. PCMCs were collected after 
6 and 24 h and were assessed for VEGF expression. As shown 
in Figure  3, the separation of bacteria and mast cells did not 
obviate the upregulation of VEGF in mast cells at 6 h, suggesting 
that soluble factors released during co-culture of mast cells and 
S. aureus can account for the induction of VEGF in mast cells. 
However, it is notable that increased VEGF induction between 
6 and 24 h was seen in the direct contact situation, whereas the 
induction was reduced over time when mast cells and bacteria 
were separated. This indicates that direct cell–cell contact may be 
required for sustained VEGF induction at high levels.
VegF Upregulation in S. aureus-
stimulated Mast cells is independent on 
nFaT but Partly Dependent on nF-κB
The inhibition of NFAT, a signaling molecule that previously has 
been shown to have role in the induction of pro-inflammatory 
genes in mast cells (18, 19), did not significantly affect the 
induction of VEGF by S. aureus (Figure 4). In contrast, NF-κB 
inhibition produced a modest, yet significant, reduction in VEGF 
expression in mast cells (Figure 4). Hence, the upregulated VEGF 
expression in mast cells stimulated with live S. aureus is partly 
dependent on the NF-κB signaling pathway.
DiscUssiOn
Mast cells are emerging as major detrimental effector cells in 
numerous pathophysiological conditions, not only in allergy 
but also in diverse processes such as autoimmune disease, 
atherosclerosis, cancer, obesity, and contact dermatitis (20, 21). 
On the other hand, mast cells can also be beneficial to their 
FigUre 4 | effect of nF-κB, and nFaT inhibition on VegF expression 
in S. aureus-stimulated mast cells. Mast cells (PCMCs) were 
preincubated with inhibitors of NFAT (11R-VIVIT) or NF-κB [6-amino-4-(4-
phenoxyphenylethylamino)quinazoline] followed by co-culture with S. aureus 
(SA) for 2 or 6 h. VEGF expression was assessed by qPCR. Results are given 
as mean ± SD, *p < 0.05, and ****p < 0.0001 (n = 3–4).
FigUre 3 | Upregulation of VegF does not require direct contact 
between S. aureus and PcMcs. Staphylococcus aureus (SA) was 
co-cultured for 6 h (a) or 24 h (B), either in direct contact or in Transwell 
conditions as indicated. Cells were recovered and were analyzed for VEGF 
expression by qPCR. Results are given as mean ± SD, *p < 0.05, and 
***p < 0.001 (n = 3).
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host, as exemplified by the contribution of mast cells to the host 
response against bacterial insult (1–3). Although the mechanism 
by which mast cells influence these processes can vary, there is 
a widespread notion that mast cells are a source of numerous 
growth factors, such as basic fibroblast growth factor, nerve 
growth factor, platelet-derived growth factor, and VEGF (21). 
Among these, the expression of VEGF by mast cells has attracted 
particular attention because of the implication of mast cells in 
malignant processes, where mast cells are thought to promote 
tumor angiogenesis by secreting growth factors including VEGF 
(22–25). However, although mast cells are emerging as major 
VEGF-producing cells, there is still limited knowledge of the 
mechanisms of VEGF induction in mast cells.
Here, we report that mast cells can be induced to express high 
levels of VEGF in response to bacterial insult, thus introducing 
a bacteria–mast cell axis as a mechanism for production of this 
growth factor. It is also important to stress that most previous 
studies in which mast cells were shown to express VEGF were 
focused on relatively immature mast cells, whereas we here 
report VEGF expression by fully mature mast cells. Interestingly, 
we noted a robust release of VEGF already after 2  h, whereas 
the onset of VEGF gene expression occurred at a later stage. 
This indicates that the early VEGF secretion is due to release of 
preformed VEGF from stores in granules, whereas the induction 
of VEGF gene expression may serve to maintain high levels of 
VEGF release after the preformed stores have been emptied.
The expression of VEGF in response to bacterial challenge 
could potentially have various pathophysiological consequences. 
One obvious scenario could be that mast cell-derived VEGF 
could have a role in the angiogenesis that accompanies the wound 
healing process following a bacterial infection. Alternatively, mast 
cell-expressed VEGF could promote vascular permeability and 
leukocyte attraction, thereby contributing to the primary host 
response following a bacterial insult. On a different angle, it is 
possible that VEGF expression induced in mast cells by bacteria, 
in fact, could be of relevance for the progress of malignant pro-
cesses. Several species of bacteria and bacterial strains are known 
to populate tumors. These bacteria may either be the cause of 
the tumor or may represent an opportunistic infection occurring 
as a consequence of the immunosuppressed status of the tumor 
tissue (26). It is also well known that mast cells populate a wide 
range of tumors, often being located at the tumor periphery but 
also within the actual tumor (7, 8). Possibly, bacteria populating 
the tumor may thus cause mast cells to upregulate their expres-
sion of VEGF, and the mast cell-derived VEGF could then have a 
pathogenic impact by promoting tumor angiogenesis.
Our findings suggest that the induction of VEGF is critically 
dependent on the interaction of mast cells with live bacteria, 
whereas various isolated bacterial cell-wall components and 
heat-inactivated bacteria were without effect. These findings are 
somewhat surprising considering that mast cells express several 
6Johnzon et al. VEGF Expression in Mast Cells
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TLRs, and that stimulation of these by various PAMPs have previ-
ously been shown to induce the expression of pro-inflammatory 
cytokines in mast cells (27–32). This suggests that the induction 
of VEGF occurs independently of TLR stimulation and, in sup-
port of this, we did not see any effect of an Myd88 inhibitor on 
VEGF expression in response to bacterial challenge. It was also 
noted that VEGF induction was not critically dependent on direct 
cell–cell contact between the bacteria and mast cells, suggesting 
that VEGF can to some extent be induced by soluble factors 
released by the bacteria. Intriguingly though, such factors were 
not found in conditioned medium obtained by culturing S. aureus 
alone, either in bacterial growth medium or in the medium used 
for culture of the mast cells. Hence, the release of factors pro-
moting VEGF expression in mast cells appears to require com-
munication between live bacteria and mast cells, leading to the 
induction and release of VEGF-driving soluble factors. Although 
we are at present not able to specify the nature of such factors, we 
noted that the induction of VEGF expression in mast cells was 
partly dependent on the NF-κB pathway. Altogether, the present 
findings suggest that soluble, VEGF-driving factors are released 
by live S. aureus as a consequence of crosstalk between live S. 
aureus and mast cells.
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